Drug Makers Press For U.S. Trade Sanctions On Thailand
This article was originally published in PharmAsia News
Drug makers are about to press the U.S. Trade Representative to impose sanctions on Thailand for refusing to drop its compulsory license moves to drive down the price of certain medicines. The director general of Thailand's Intellectual Property Department said the Pharmaceutical Research and Manufacturers of America, which met in Singapore recently, had threatened a strong lobbying effort to get the U.S. policy change. The sanction process envisioned would reduce Thailand from the Priority Watch List where it is now to Priority Foreign Country that makes a nation subject to trade sanctions. (Click here for more
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.